Xeris Biopharma (NASDAQ:XERS) Insider Kevin Mcculloch Sells 90,000 Shares of Stock

Xeris Biopharma Holdings, Inc. (NASDAQ:XERS) insider Kevin Mcculloch sold 90,000 shares of Xeris Biopharma stock in a transaction that occurred on Wednesday, July 1st. The shares were sold at an average price of $8.03, for a total value of $722,700.00. Following the completion of the sale, the insider owned 1,691,126 shares in the company, valued at approximately $13,579,741.78. This trade represents a 5.05% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Xeris Biopharma Price Performance

XERS stock traded up $0.28 on Thursday, reaching $8.28. 3,702,785 shares of the company’s stock were exchanged, compared to its average volume of 1,901,927. The stock has a fifty day moving average of $6.51 and a 200-day moving average of $6.61. The firm has a market cap of $1.43 billion, a PE ratio of 138.00 and a beta of 0.62. The company has a quick ratio of 1.50, a current ratio of 2.12 and a debt-to-equity ratio of 17.00. Xeris Biopharma Holdings, Inc. has a twelve month low of $4.62 and a twelve month high of $10.08.

Xeris Biopharma (NASDAQ:XERS) last released its earnings results on Thursday, May 7th. The company reported $0.01 EPS for the quarter. The company had revenue of $83.13 million during the quarter, compared to the consensus estimate of $79.83 million. Xeris Biopharma had a return on equity of 735.00% and a net margin of 3.81%. As a group, equities analysts predict that Xeris Biopharma Holdings, Inc. will post 0.12 EPS for the current fiscal year.

Wall Street Analyst Weigh In

A number of analysts recently commented on XERS shares. Weiss Ratings downgraded shares of Xeris Biopharma from a “hold (c-)” rating to a “sell (d+)” rating in a report on Monday, May 11th. Wall Street Zen upgraded shares of Xeris Biopharma from a “buy” rating to a “strong-buy” rating in a research report on Saturday, March 7th. Four research analysts have rated the stock with a Buy rating, two have assigned a Hold rating and one has given a Sell rating to the stock. According to MarketBeat.com, the stock presently has a consensus rating of “Hold” and a consensus target price of $10.80.

Institutional Investors Weigh In On Xeris Biopharma

A number of large investors have recently bought and sold shares of the stock. Divisadero Street Capital Management LP acquired a new position in Xeris Biopharma in the 3rd quarter valued at about $3,308,000. Apella Capital LLC boosted its stake in shares of Xeris Biopharma by 2,359.0% during the 4th quarter. Apella Capital LLC now owns 245,897 shares of the company’s stock worth $1,930,000 after purchasing an additional 235,897 shares during the last quarter. Granahan Investment Management LLC purchased a new stake in shares of Xeris Biopharma during the third quarter worth about $2,850,000. Vanguard Group Inc. grew its holdings in shares of Xeris Biopharma by 13.8% during the fourth quarter. Vanguard Group Inc. now owns 11,186,677 shares of the company’s stock worth $87,815,000 after buying an additional 1,358,760 shares in the last quarter. Finally, WINTON GROUP Ltd acquired a new position in shares of Xeris Biopharma in the third quarter valued at approximately $739,000. Institutional investors and hedge funds own 42.75% of the company’s stock.

Xeris Biopharma Company Profile

Xeris Biopharma is a clinical-stage biopharmaceutical company focused on developing and commercializing novel therapies for endocrine and orphan diseases. The company’s proprietary formulation platform is designed to enable liquid stability of drugs that traditionally require reconstitution before injection. By eliminating the need for on-site mixing and simplifying administration, Xeris aims to improve patient safety, adherence, and convenience in high-need therapeutic areas.

The company’s flagship product, Gvoke, is a ready-to-use liquid glucagon autoinjector and prefilled syringe that has been approved by the U.S.